Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
TCP1
T‐cell lymphomas
follow‐up
outcome
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
revised:
27
02
2024
received:
31
10
2023
accepted:
16
03
2024
medline:
27
3
2024
pubmed:
27
3
2024
entrez:
27
3
2024
Statut:
aheadofprint
Résumé
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long-term outcome analysis on patients from the ITCLP with available 10-year follow-up data (n = 735). The overall response rate to first-line therapy was 68%, while 5- and 10-year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5- to 10-year period (67%). Low-risk International Prognostic Index and Prognostic Index for T-cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2-4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front-line therapeutic approaches in PTCLs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Associazione Angela Serra per la Ricerca sul Cancro
Organisme : Fondazione Italiana Linfomi
Organisme : Fondazione Cassa di Risparmio di Modena
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Vose JM, Armitage J, Weisenburger D, International T‐cell Lymphoma Project. International peripheral T‐cell and natural killer/T‐cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the international T cell project network. Br J Haematol. 2018;181(6):760–769.
Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, et al. Outcomes and prognostic factors in angioimmunoblastic T‐cell lymphoma: final report from the international T‐cell project. Blood. 2021;138(3):213–220.
Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, et al. Incidence and outcomes of rare T cell lymphomas from the T cell project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol. 2020;95(2):151–155.
Chiattone C, Civallero M, Fischer T, Miranda E, Manni M, Zing NP, et al. Characteristics and clinical outcomes of patients with ALK‐positive anaplastic large cell lymphoma: report from the prospective International T‐cell Lymphoma Project. Hematol Oncol. 2022;40(5):953–961.
Shustov A, Cabrera ME, Civallero M, Bellei M, Ko YH, Manni M, et al. ALK‐negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the international T‐cell project. Blood Adv. 2021;5(3):640–648.
International Non‐Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non‐Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–994.
Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T‐cell lymphoma unspecified (PTCL‐U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479.
Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, Souza CA, et al. T‐cell lymphomas in South America and Europe. Rev Bras Hematol Hemoter. 2012;34:42–47.
Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T‐cell lymphoma patients failing first‐line therapy: a report from the prospective, international T‐cell project. Haematologica. 2018;103(7):1191–1197.
Casulo C, Dixon JG, Le‐Rademacher J, Hoster E, Hochster HS, Hiddemann W, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684–1693.
Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event‐free survival at 24 months is a robust end point for disease‐related outcome in diffuse large B‐cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073.
Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, et al. International assessment of event‐free survival at 24 months and subsequent survival in peripheral T‐cell lymphoma. J Clin Oncol. 2017;35(36):4019–4026.
Relander T, Pedersen MB, Ellin F, Lauritzsen GF, Jantunen E, Hagberg H, et al. Long‐term follow‐up of clinical outcome determinants and correlative biological features from the Nordic NLG‐T‐01 trial. Blood. 2022;140(Suppl 1):1479–1480.
Brink M, Meeuwes FO, van der Poel MW, Kersten MJ, Wondergem M, Mutsaers PG, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population‐based cohort study. Blood. 2022;140(9):1009–1199.
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas‐Virelizier E, Toussaint E, et al. Role of up‐front autologous stem‐cell transplantation in peripheral T‐cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29(3):715–723.
Al‐Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for high risk aggressive T‐cell non‐Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leuk Lymphoma. 2019;60(8):1934–1941.
Horwitz S, O'connor OA, Pro B, Trümper L, Iyer S, Advani R, et al. The ECHELON‐2 trial: 5‐year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30‐positive peripheral T‐cell lymphoma. Ann Oncol. 2022;33(3):288–298.
Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai SV, et al. Romidepsin‐CHOEP followed by high‐dose chemotherapy and stem‐cell transplantation in untreated peripheral T‐cell lymphoma: results of the PTCL13 phase Ib/II study. Leukemia. 2023;37(2):433–440.
Ghione P, Faruque P, Mehta‐Shah N, Seshan V, Ozkaya N, Bhaskar S, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T‐cell lymphoma. Blood Adv. 2020;4(19):4640–4647.
Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK‐negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–1480.
Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, et al. GATA‐3 expression identifies a high‐risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007–3015.